Compare Quest Diagnostics Inc (DGX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Toyota Motor Corp — how do they compare? Quest Diagnostics Inc trades at $230.04 (market cap $25.48B), while Toyota Motor Corp trades at $184.7 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 8.5× Quest Diagnostics Inc's market cap, and Toyota Motor Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Toyota Motor Corp for 116 Days on average.
| DGX | TM | |
|---|---|---|
Market Cap | $25.48B | $217.38B |
Volume | 941,866 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $248.29 |
52-Week Low | $173.49 | $166.50 |
Typical Hold Time | 56 Days | 116 Days |
Enterprise Value | $31.23B | $410.96B |
Dividend Yield | 1.49% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while consistently beating earnings expectations in recent quarters. Recent news highlights Toyota's growing U.S. market share and electrification progress with 37.8% growth in EV sales. Cash flow trends show improvement with projected 2026 operating cash flow of $4.13T.
Toyota presents a value opportunity with solid profitability and market positioning, though near-term technical weakness and China sales challenges warrant caution. The company's hybrid technology leadership and North American expansion provide growth catalysts, while analyst consensus leans neutral with 62.5% hold ratings. Debt levels remain manageable at 41.29% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
